WASHINGTON (dpa-AFX) - ANI Pharmaceuticals Inc. (ANIP) said that it has acquired the U.S. portfolio of 23 generic products from Amerigen Pharmaceuticals Ltd. for $52.5 million in cash at close and up to $25 million in contingent profit share payments over the next four years.
The acquired portfolio includes ten commercial products, three approved products with launches pending, four filed products and four in-development products as well as a license to commercialize two approved products.
Copyright RTT News/dpa-AFX
© 2020 AFX News
